300347:SZSEHangzhou Tigermed Consulting Co., Ltd. Class A Analysis
Data as of 2026-05-23 - not real-time
CN¥42.32
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Hangzhou Tigermed is trading well below its short‑term, medium‑term and long‑term simple moving averages, indicating a pronounced bearish price trend. The RSI is deep in oversold territory and the MACD shows a bearish divergence, while volume has been rising, suggesting some accumulation near the recent support level.
Fundamentally, the company delivers solid top‑line growth and generates healthy cash flow, but margins are modest, ROE is low and the balance sheet shows a high debt‑to‑equity ratio. Valuation metrics such as the price‑to‑earnings multiple are markedly above industry averages and the DCF‑derived fair value is well below the current market price, pointing to an overvalued condition despite analyst buy recommendations and a modest dividend payout.
Fundamentally, the company delivers solid top‑line growth and generates healthy cash flow, but margins are modest, ROE is low and the balance sheet shows a high debt‑to‑equity ratio. Valuation metrics such as the price‑to‑earnings multiple are markedly above industry averages and the DCF‑derived fair value is well below the current market price, pointing to an overvalued condition despite analyst buy recommendations and a modest dividend payout.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price hovering just above recent support
- oversold momentum indicators
- rising trading volume indicating potential short‑term accumulation
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- steady revenue growth and strong cash generation
- analyst target price substantially above current level
- forward earnings multiple compressing toward industry norms
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- ongoing demand for CRO services in the healthcare sector
- elevated valuation relative to fundamentals
- moderate regulatory and geographic exposure in China
Key Metrics & Analysis
Financial Health
Revenue Growth15.20%
Profit Margin10.91%
P/E Ratio46.5
ROE4.23%
ROA1.33%
Debt/Equity7.01
P/B Ratio1.7
Op. Cash FlowCN¥1.2B
Free Cash FlowCN¥1.0B
Industry P/E27.6
Technical Analysis
TrendBearish
RSI23.3
SupportCN¥41.61
ResistanceCN¥59.50
MA 20CN¥51.34
MA 50CN¥53.43
MA 200CN¥57.65
MACDBearish
VolumeIncreasing
Fear & Greed Index91.61
Valuation
Fair ValueCN¥29.90
Target PriceCN¥65.16
Upside/Downside53.97%
GradeOvervalued
TypeBlend
Dividend Yield0.71%
Risk Assessment
Beta0.44
Volatility42.17%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.